AI-enabled medical devices with limited pre-market validation are more likely to be recalled after FDA clearance.
Key Details
- 1AI-enabled device recalls are more common among those lacking prospective human validation prior to FDA 510(k) clearance.
- 2Most AI medical devices are cleared without requiring prospective clinical testing.
- 3Study reviewed all U.S. recalls of AI-enabled devices between Nov. 15–30, 2024.
- 4Validation method (none, retrospective, or prospective) was a notable factor influencing recall likelihood.
- 5Recalls were categorized into errors such as diagnostic, measurement, and functional issues.
Why It Matters
These findings highlight the inadequacy of current FDA pathways to ensure AI device reliability and safety in clinical environments. For radiology professionals and developers, the results underscore the critical importance of robust validation before market approval.
Source
Health Imaging
Related News
•Radiology Business
RadNet Study: AI Boosts Breast Cancer Detection in Largest-Ever Real-World Analysis
A massive real-world study by RadNet shows AI-assisted mammography increased breast cancer detection by 21.6%.
•AuntMinnie
Multimodal MRI Radiomics Model Predicts Long-Term Survival in Breast Cancer
A multimodal MRI radiomics and deep learning model outperformed traditional models in predicting 5- and 7-year survival for breast cancer patients receiving neoadjuvant chemotherapy.
•AuntMinnie
AI Predicts 10-Year Mortality and Hip Fracture Risk from DEXA Scans
A self-supervised AI model predicts 10-year mortality and hip fractures using only DEXA scans.